文献速递神经儿科影像MR

儿童视路胶质瘤随访中非增强MRI检查的诊断效能

Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children.
PubMed 文献 · Neuroradiology · 2019-03-23

研究纳入2001至2017年17例儿童视路胶质瘤患者,以放射报告结论为金标准,回顾25例肿瘤进展和25例稳定病例,由两名放射科医生独立评估非增强MRI的定量(肿瘤体积变化)和定性标准。非增强MRI诊断肿瘤进展的敏感度为84-88%(95%CI 63.9-97.5),特异度为91.3-100%(95%CI 72-100),观察者间一致性优秀(kappa=0.87,p<0.001)。作者认为肿瘤体积变化在多数情况下足以评估视路胶质瘤进展,系统性增强MRI可存疑。

要点

  • 非增强MRI随访儿童视路胶质瘤,肿瘤体积变化在多数情况下足以评估进展。
  • 非增强MRI诊断进展的敏感度84-88%,特异度91.3-100%,观察者间一致性优秀(kappa=0.87)。
  • 作者认为系统性增强MRI的必要性可存疑。

核心结论

  • 肿瘤体积变化在多数情况下足以评估儿童视路胶质瘤进展,系统性增强MRI的必要性可存疑。

研究设计与样本

  • 回顾性研究,纳入2001至2017年17例儿童视路胶质瘤患者(伴或不伴NF1),每例至少有5次增强MRI脑部随访检查;以放射报告结论中提及的25例肿瘤进展和25例肿瘤稳定为金标准。

诊断标准与关键数值

  • 非增强MRI诊断肿瘤进展的敏感度为84-88%(95%CI 63.9-97.5),特异度为91.3-100%(95%CI 72-100);读者1的阳性预测值为91.7%、阴性预测值为87.5%,读者2的阳性预测值为100%、阴性预测值为85.2%;观察者间一致性kappa系数为0.87(p<0.001);两次检查间肿瘤体积变化百分比的观察者间和观察者内变异相关系数分别为0.97和0.94。

临床应用与阅片要点

  • 作者认为肿瘤体积变化在多数情况下足以评估视路胶质瘤进展,系统性增强MRI的必要性可存疑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Contrast-enhanced MRI (MRI + C) is considered as mandatory for brain tumors follow-up, but gadolinium brain depositions in relation with repeated injections have been reported. The aim of our work was to evaluate the diagnostic performance of an unenhanced MRI examination for the follow-up of optic pathway gliomas (OPG) in children.

METHODS: Seventeen patients (with/without NF1) were selected from 2001 to 2017, with at least 5 MRI + C brain follow-up examinations. Privacy and data protection rights were addressed by the data protection officer (DPO) and the study was in accordance with the local ethical rules. Twenty-five cases of tumor progression and 25 cases of tumor stability mentioned in the conclusion of radiological reports (defined as gold standard) were isolated. Those exams were anonymized and independently reviewed by two radiologists, who analyzed both quantitative (such as tumor volume variation) and qualitative criteria (such as ventricular dilatation) on unenhanced images. Sensitivity, specificity, positive/negative predictive values (PPV, NPV), and inter/intra-observer agreement were calculated.

RESULTS: The mean age of patients was 5.4 ± 3.4 years and mean follow-up length 6.7 years. The mean number of MRI + C was 13.5 (SD 7.2). The sensitivity of unenhanced MRI for tumor follow-up was 84-88% (95% CI 63.9-97.5). The specificity was 91.3-100% (95% CI 72-100). The PPV was 91.7% for reader 1 and 100% for reader 2. The NVP was 87.5% for reader 1 and 85.2% for reader 2. There was an excellent inter-observer agreement regarding tumor progression: kappa coefficient of 0.87 (p < 0.001). Inter/intra-variability for percentage of tumor volume variation between two exams were good (correlation coefficients of 0.97 and 0.94).

CONCLUSION: Tumor volume variation is in most cases sufficient to assess OPG progression. Systematic MRI + C could be questionable.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Marsault P, Ducassou S, Menut F, et al. Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children. Neuroradiology. 2019. PMID: 30904949. doi:10.1007/s00234-019-02198-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。